NCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06906562 2026-02-17
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06302621 2026-01-15
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1 Recruiting
NCT04659616 2025-12-19
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT06300528 2025-12-03
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
Phase 2 Recruiting
NCT06653777 2025-06-05
AcSé PEMI
UNICANCER
Phase 2 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT05004974 2024-03-12
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Recruiting
NCT05651672 2022-12-15
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting